Core Insights - Stereotaxis (STXS) has partnered with CardioFocus to develop the first robotic Pulsed Field Ablation (PFA) system for treating cardiac arrhythmias, combining robotic precision with advanced PFA technology to enhance clinical use and commercialization [1][6][8] Company Summary - The collaboration is expected to leverage the strengths of both companies, enhancing treatment options in electrophysiology and expanding their presence in the growing cardiac care market [2][4] - Stereotaxis aims to integrate CardioFocus's CE-marked Centauri PFA System into its robotic platform, enhancing its product portfolio and creating new revenue streams in the cardiac ablation market [4][11] - STXS currently has a market capitalization of $279.6 million and reported an earnings surprise of 28.6% in the last quarter [5] Market Trends - The global pulsed field ablation market is projected to grow from an estimated size of $913.1 million in 2024 at a CAGR of 33.1% from 2025 to 2030, driven by the rising prevalence of atrial fibrillation and the adoption of minimally invasive procedures [12]

Core Insights - Stereotaxis and CardioFocus have entered a Collaboration Agreement to advance robotic Pulsed Field Ablation (PFA) technology for cardiac arrhythmias [1][2][3] Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, having treated over 150,000 patients globally [5] - CardioFocus specializes in pulsed field ablation treatment for cardiac disorders, particularly atrial fibrillation, and has developed the Centauri PFA System, which has been used on over 9,000 patients in Europe [6] Collaboration Details - The collaboration aims to combine the Centauri PFA System with Stereotaxis' MAGiC robotic cardiac ablation catheter, enhancing the efficiency and safety of cardiac ablation procedures [2][3] - Extensive bench and preclinical testing have shown that the combination of Centauri and MAGiC delivers safe and efficient lesion delivery, including durable lesions in ventricular tissue [3] Clinical and Regulatory Progress - The partnership supports advancing the joint solution to clinical trials, facilitating regulatory compatibility and commercial availability [3] - Both companies anticipate transitioning to first human use and advancing the regulatory process in the coming months [4]